Sector Experts

Grant Zeng

Zacks Investment Research , Zacks Small-Cap Research

Image: Grant Zeng

Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).




Recent Interviews

Build Biotech Wealth on Solid Platforms: Grant Zeng (4/17/14) Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

6 Biotechs with Staggering Potential: Grant Zeng (4/4/13) When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.

Recent Quotes

"NEO is becoming America's premier cancer testing laboratory." (7/21/14) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"SNGX is aggressively pursuing government stockpile contracts." (5/12/14) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We continue to rate NEO's shares Outperform." (4/24/14) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >

"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More >

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More >

"We are optimistic about SNGX's lead candidate SGX942." (3/26/14) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We maintain an Outperform rating for SNGX; we think the company's shares are undervalued at this time." (3/26/14) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

more comments

"DMPI reported positive VAL-083 phase 1/2 data for brain cancer." (3/14/14) DelMar Pharmaceuticals Inc. - Grant Zeng, Zacks Small-Cap Research More >

"NEO reported record revenue for Q4/13, the highest in its history." (2/20/14) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"SNGX is on track to advance multiple clinical programs." (2/18/14) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We are upgrading DMPI's rating to Outperform." (11/27/13) DelMar Pharmaceuticals Inc. - Grant Zeng, Seeking Alpha More >

"SNGX's valuation is attractive at this time based on the fundamentals; we rate the shares Outperform." (11/12/13) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We continue to rate NEO Outperform based on its strong fundamentals." (10/13/13) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"NEO reported record revenue for H1/13." (9/30/13) NeoGenomics Laboratories - Grant Zeng, Seeking Alpha More >

"We continue to rate NEO Outperform based on its strong fundamentals." (7/31/13) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"GALE is making progress in three clinical programs." (6/4/13) Galena Biopharma Inc. - Grant Zeng, Zacks Small-Cap Research More >

We continue to rate NEO Outperform based on its strong fundamentals." (4/26/13) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >

"NEO is a small but focused diagnostic company with numerous competitive advantages." (4/4/13) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >

"We continue rate GALE Outperform." (3/19/13) Galena Biopharma Inc. - Grant Zeng, Zacks Small-Cap Research More >

"NEO's NeoSite will further grow its top line in coming quarters." (12/28/12) NeoGenomics Laboratories - Grant Zeng, Zacks Investment Research More >

"The transition to the NASDAQ reflects NEO's strong revenue growth." (12/28/12) NeoGenomics Laboratories - Grant Zeng, Zacks Investment Research More >

"We continue to rate NEO shares Outperform." (11/5/12) NeoGenomics Laboratories - Grant Zeng, Zacks Investment Research More >

fewer comments


Due to permission requirements, not all quotes are shown.